Hanmi Science Posts Q3 Revenue of 362.9 Billion Won; Operating Profit Down 51%

Revenue up 5.9% on growth in pharmaceutical distribution
Online Pharm revenue reaches 308.1 billion won, up 7.3%

Hanmi Science, the holding company of Hanmi Group, continued to grow its top line in the third quarter of this year, driven by growth in pharmaceutical distribution and healthcare businesses.

Hanmi Science provisionally disclosed on October 27 that it posted consolidated revenue of 362.9 billion won, operating profit of 19.2 billion won, and net profit of 15.6 billion won in the third quarter. Revenue rose 5.9% year over year, while operating profit and net profit fell 51.3% and 51.1%, respectively. The company said the declines in operating profit and net profit reflected a high base from the same period last year, when Hanmi Pharmaceutical generated revenue from technology exports.

A view of Hanmi Group's headquarters in Songpa-gu, Seoul. Hanmi Science

The company said the results were driven by balanced growth across group affiliates, including its pharmaceutical distribution business, Online팜, and its own healthcare business. Online팜 posted revenue of 308.1 billion won, up 7.3% year over year, supported by expansion of its domestic distribution business centered on prescription drugs (ETC).

Hanmi Science is expanding the competitiveness of its own businesses in various areas, beyond its role as a holding company. In the medical device business, strong performance from key products such as Gadix and Acticlot, along with increased sales of LiquiBand XL and enhanced business competitiveness for products such as SurgiGuard, contributed to growth.

Sales of new products from PRO-CALM, a derma-cosmetics brand exclusively for pharmacies, also remained solid. Performance was further supported by expanded business-to-consumer (B2C) channel sales of Wanjeon Soy Milk, an all-soy beverage, and the entry of Care Me, an all-in-one nutritional food brand, into new home-shopping and pharmacy channels. In addition, the company is broadening its portfolio into the wellness and beauty markets through NPLE, a health functional food brand, and ADESII, a derma-cosmetics brand.

A Hanmi Science representative said, "We will focus all our capabilities on becoming a global healthcare leader by organically expanding our business portfolio, from medical devices to consumer health, wellness, and beauty, strengthening our competitiveness, and maximizing synergies among our affiliates."

This content was produced with the assistance of AI translation services.